For the second year in a row, COVID-19 is the most pressing topic in the pharmaceutical industry. In an article by AIS Health, industry leaders project the landscape of pharma in 2022. A key trend that Mike Delone of Deloitte Consulting LLP predicts will continue this year is the increasing […]
Study Finds Racial Bias Embedded in Electronic Health Records
Although ostensibly objective observations of patient information, a new study in Health Affairs shows that electronic health records (EHR) reveal racial bias on the part of clinicians. According to the study, negative language was 2.54 times as likely to be present in the EHR of Black patients than […]
FAIR Health Releases COVID-19 Cost Tracker Brief
In a new brief released by FAIR Health, 2020-2021 private healthcare claims data was analyzed to deliver state by state COVID-19 costs. Leading the chart in cost per hospitalization was New Jersey with an average of nearly $129 thousand, which dwarfed that of Maryland, the lowest state on the list […]
Dr. Samantha Roberts Announced as New NICE Chief Executive
NICE has announced that Dr. Samantha Roberts, currently Managing Director for Health and Care at Legal and General, will take the role as the new Chief Executive of NICE. Roberts, who has two decades of experience in healthcare, will replace outgoing Chief Executive Dr. Gillian Leng. Dr. Roberts […]
2021 Virtual ISPOR Europe Presentations are Available from Cytel
Cytel is now offering slide decks for the presentations that its health economics and outcomes research and real-world evidence experts presented at the ISPOR Europe 2021 conference. Presentations include: “Transcatheter Versus Surgical Aortic Valve Replacement - a Real-World Comparison of Clinical […]
Market Competition Benefits from Price Regulation
In a new publication in the journal Health Affairs, authors Robert A. Berenson and Robert B. Murray make the case that healthcare price regulation is needed to promote competition within providers and insurers. The authors argue that by regulating prices, more providers and insurers can enter the […]
Systemic Review: Real-World Data for Healthcare Research in China
Despite the emergence of several new sources of real-world evidence for healthcare in China, little has been done to evaluate these resources. A study published in Value in Health Regional Issues found that many of these databases are of insufficient quality to further health economics and outcomes […]
Veranda Health Announces New Funding Round by Johnson & Johnson
Veranda Health, a company that uses a real-world data (RWD) network to produce drug lifecycle and medical practice insights, has announced new funding from Johnson and Johnson. The deal, which amounts to $150 million, will be used to further develop their life science data services to deliver better […]
Biden’s LGBTQ Healthcare Anti-Discrimination Proposal Mired in Legal Challenges
An anti-discrimination rule proposed by the Biden administration to protect LGBTQ people is already facing legal challenges. The rule, an expansion of a previous Health and Human Services policy, would prevent federally-funded health programs from discriminating based on sexual orientation or gender […]
Study Uncovers Racial Bias in Electronic Health Records
A new study published in Health Affairs reveals extensive racial bias documented in electronic health records (EHR). By analyzing over 40,000 history and physical notes from January 2019 – October 2020, authors Michael Sun and colleagues found that Black patients were 2.54 times more likely to have […]
Infographic – By the Numbers: National Health Insurance Marketplace Dec ‘21
AIS Health, an MMIT company, has released a new infographic detailing the landscape of the US health insurance marketplace in December 2021. The infographic details levels of enrollment by the line of business, the top insurers in several different markets, and top Blues plans. The infographic is […]
Call for Abstracts: R for Health Technology Assessment Workshop
Abstract submissions are open for the R for Health Technology Assessment (HTA) workshop hosted by St. Anne’s College, University of Oxford, on May 19th-20th and the 23rd, 2022. The workshop is a daylong in-person hybrid event showcasing presentations on using R for HTA-related purposes. Participants […]
Are Virtual Advisory Boards Here to Stay?
The COVID-19 pandemic hastened the transition from in-person advisory board meetings to a virtual format. However, this was not a smooth change, and challenges for successful and engaging adoption of entirely-online advisory meetings still remain. In a recent MAP Newsletter, authors break down these […]
AJMC Study: Projected US Savings from Biosimilars, 2021-2025
In a recent study published in the American Journal of Managed Care, researchers Andrew Mulcahy, PhD, and colleagues project US spending on biosimilars and estimate the total savings provided by them from 2021-2025. Mulcahy et al. estimate that biosimilars would save $38.4 billion in this time frame […]
New Independent Directors Appointed by Syneos
Syneos Health has announced that it has appointed Barbara W. Bodem and Alfonso G. Zulueta to its Board of Directors. The two new independent directors bring their insights to help the company’s customers get their therapeutics to patients. Bodem was the Senior Vice President and Chief Financial […]
Rare Disease Clinical Outcome Assessment Consortium Announced by C-Path
The Critical Path Institute (C-Path) has launched its Rare Disease Clinical Outcome Assessment Consortium. The Consortium is a public-private collaborative effort to help select clinical outcome assessment parameters for therapeutics and products targeting rare diseases. Partners in this effort […]
Clarivate Releases 2022 Drugs to Watch List
Clarivate has released their 2022 Drugs to Watch list. The list includes seven experimental therapeutics in the pipeline that have the potential to advance public health and become heavy hitters for pharma. These drugs include lecanemab, an Alzheimer’s drug, adagrasib, a cancer drug, and the type 2 […]
US faces ‘critical moment’ in pricing reform that ‘won’t come again,’ nonprofit founder says after tallying 554 new hikes
With 2021 over, the pharmaceutical industry kicked off the New Year with one of its favorite pastimes: raising the prices on hundreds of branded meds. Public and political scrutiny didn’t stop many of the world's top drugmakers from partaking in the customary practice. Still, a shot at […]
A holistic approach to market access in emerging markets
Although his focus is usually on the APAC region, Jeff’s observations can be applied to emerging markets in other parts of the world, including Africa and Latin America. Though each market has its own unique features, grouping markets into archetypes can be a useful approach in developing access […]
Why Are Physicians Silent About Outrageous Drug Prices?
One of the bizarre aspects of drug pricing in the U.S. is that the government is not permitted by law to negotiate the prices of drugs with pharmaceutical manufacturers. In most of the world markets, the national health authority in each country engages in long (and often difficult) discussions with […]
Supply chain middlemen ‘pocket half of US branded medicine spending’
In 2020, over half of total spending on brand medicines went to the supply chain, middlemen and other stakeholders, overtaking the amount going to drug manufacturers for the first time, according to a new study. The report from Berkeley Research Group (BRG) – which was funded by the pharma […]
Innovation and access: Improving Europe’s pharmaceutical regulatory framework
EMA “lags behind” other international regulators when it comes to approval timelines, finds EFPIA analysis. Only a regulatory framework that “embraces a culture of excellence and innovation” will make Europe a world leader in life sciences and ensure people can reap the benefits of life-changing […]
NORD’s Rare Cancer Coalition 2021 Year In Review
Jan. 12, 2022 TOPIC: Patients & Members [NORD’s Rare Cancer Coalition 2021 Year In Review] Posted by Maia Craig NORD’s Rare Cancer Coalition (RCC) worked hard in 2021 to raise awareness for rare cancers and tackle issues that patients and caregivers face, such as access to care, treatments, and […]
C-Path Launches Rare Disease Clinical Outcome Assessment Consortium
The Rare Disease COA Consortium aims to advance patient-focused assessment of clinical benefit in treatment trials for rare diseases TUCSON, the launch of the a public-private partnership focused on optimizing COA selection during medical product development for rare diseases. The Rare Disease COA […]
UNC researchers awarded $4.3M from PCORI to study strategies to improve health outcomes for youth with intellectual and developmental disabilities and their parents
Kathleen C Thomas, PhD, MPH of the UNC Eshelman School of Pharmacy will lead a comparative effectiveness research study to improve health outcomes for youth with intellectual and developmental disability (IDD) and their parents through two parent peer group interventions, one parent-directed and one […]
Turning the deluge of health data into actionable health analytics
At the time, the HITECH Law 2009 and the introduction of the meaningful use program represented a momentous step in the digital transformation of healthcare. With billions of dollars in investment and government incentives in almost two years, more than 77% of hospitals had reached stage 3 of the […]
J&J’s investment arm joins $150M investment in digital health firm Verana
Medical full body screening software on tablet and healthcare devices Verana Health, a company that analyzes real-world patient data to provide insights about drugs, has raised $150 million to fuel an expansion of its technology. Data from more than 20,000 healthcare providers and 70 electronic […]
DNA Explainer: Why Govt plans to study drug pricing policies of other countries
Centre is planning to start a study on drug pricing policies of at least 10 countries, including China, Sri Lanka, Bangladesh and the United States. This comes at a time when prices of medicines are going up and the ongoing Covid-19 pandemic has added to the woes. The affordability of medicines is a […]
Klobuchar optimistic Medicare will be given some power to negotiate drug prices
Klobuchar optimistic Medicare will be given some power to negotiate drug prices U.S. Sen. Amy Klobuchar says there’s no good reason why Medicare is barred by law from being able to use its clout to negotiate lower prescription drug prices. The Minnesota Democrat has been calling for a law change […]
The Drug Industry Might Have Dodged A Build Back Better Bullet But Remains In Congressional Crosshairs
The Biden administration’s campaign to rehabilitate the drug price negotiation legislation contained in the stalled Build Back Better bill (BBB), appears to have been sidelined for now. Reluctant senators and Covid-19 have all but eliminated any new year’s momentum to pass it. With time running out, […]
